Pharmacological Treatment of Acute Coronary Syndromes
Authors:
F. Holm; M. Aschermann 1
Authors‘ workplace:
Kardiologické oddělení, Krajská nemocnice Liberec 1II. interní klinika 1. LF UK a VFN, Praha
Published in:
Čas. Lék. čes. 2003; : 456-459
Category:
Overview
Acute coronary syndromes (ACS) are caused by neoinclusive thrombosis of the coronary artery. Arterial atherothrombosisusually results from a cracked atheroma plate and includes platelet and plasmatic component ofcoagulation. The aim of pharmacological treatment is to influence activated platelets and plasma procoagulantactivity. Several clinical studies have demonstrated the benefits of antithrombotic treatment by acetylsalicylic acid,clopidogrel and by blockers of platelet receptors IIb/IIIa. In ACS anticoagulant therapy the non-fractionated heparinare replace ed by low-molecular heparins. The new standard in ACS therapy should become a combination of theacetylsalicylic acid, enoxaparine and clopidogrel. Blockers of platelet receptors IIb/IIIa should be given namely topatients indicated for the early invasive treatment.
Key words:
acute coronary syndrome, pharmacotherapy.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Urocanic Acid and its Role in Photoimmunomodulation
- Bartter’s Syndrome – Hypokalemic Renal Tubular Syndrome
- Treatment of Helicobacter pylori Infection in Stomach and Duodenum Ulcers
- Hepcidin – The Peptide Regulating the Body Amount and Distribution of Iron in Health andDisease